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Abstract
Background: SEN virus (SENV) and Torque teno virus (TTV) are blood 
born viruses. Their effect on the development and progress of liver 
diseases is still unclear. The aim of this study was to determine the 
prevalence and effect of SENV and TTV among chronic hepatitis C 
(CHC) patients. 
Patients and Methods: Two hundred patients with CHC were the 
subjects of this work. A single blood sample was collected from each 
patient. Thorough clinical examination and relevant laboratory and 
radiological investigations were done. SENV and TTV were tested for 
by Polymerase Chain Reaction (PCR). 
Results: SENV was identified in 3 (1.5%) and TTV was found in 21 
(10.5%) of investigated patients. No statistically significant difference 
was detected as regards clinical status, laboratory findings or radiologi-
cal examination between SENV or TTV positive and negative patients. 
Conclusion: SENV and TTV exist among CHC patients. They had 
insignificant implications on the course or progression of liver diseases.
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Introduction
HCV infection is a public health problem in Egypt, the country with 
the highest prevalence rate worldwide. With the introduction of the 
direct acting antivirals (DAAs) active against HCV in 2014, the story 
has seemed to come to the end. In order to achieve the objective Received 21-05-2019; Accepted 19-07-2019
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of eradication of HCV by 2030, many DAAs are 
available and are easily accessible in Egypt inclu-
ding sofosbuvir, daclatasvir, simeprevir, idvipasivir, 
ombitasvir, paritaprevir and ritonavir. Guidelines for 
treatment of various categories of Egyptian HCV 
patients have been developed by the National Com-
mittee for Control of Viral Hepatitis (NCCVH) and 
are being regularly updated [1]. For better mana-
gement of CHC patients it is important to assess 
the impact of concomitant infections on the clinical 
course and the progression of the disease.
In the last few years, SENV and TTV have been 
described as new blood-borne, hepatotropic viral 
agents with possible hepatic pathogenicity [2].
SEN virus (SENV) is the latest virus proposed as 
a cause of unknown hepatitis cases. The virus is 
a circular, single-stranded DNA virus, with around 
3800 nucleotides long and nearly 26 nm size. It is 
non-enveloped and has a minimum of three ORFs 
[3]. In the base of investigations on ORF1 sequen-
ces, SENV has been classified in the Anellovirusge-
nus [4]. Nine genotypes (A to I) with about 25% 
differences in nucleotide sequence are known [5]. 
Among the nine genotypes, SENV-D and SENV-H 
genotypes are the most frequently isolated from 
cases of (non- A to E) hepatitis. However, they are 
also frequent in the sera of healthy blood donors 
[6]. SENV is ubiquitous with distinct geographic 
variation [7].
TTV has been discovered in 1997 (Japan) in the 
bloodstream of a patient with post-transfusion he-
patitis. It was the first human virus with a single-
stranded circular DNA genome to be identified 
[8]. TTV has recently been classified as the Alpha-
torque virus genus within the Anelloviridae family 
by the International Committee on Taxonomy of 
Viruses (ICTV). Thus far, five main genetic groups 
(Groups 1-5) involving at least 39 genotypes have 
been identified based on phylogenetic analysis. 
SENV and TTV are identified among wide ranges 
of populations including intravenous drug users 
[9], hemophilic and thalassemic patients [10], pa-
tients on maintenance hemodialysis [11], HIV po-
sitive [12] and patients with hepatic disease [8]. 
Lin et al. have reported that SEN-V is sensitive to 
interferon (IFN) therapy [13]. After the stoppage 
of IFN therapy on HCV patients co-infected with 
SENV, the later was eradicated in 77% while the 
former was eliminated in 38% of patients. These 
reflect the higher sensitivity of SENV virus to IFN 
therapy than that of HCV. Combined treatment 
with ribavirin (RBV) therapy does not affect SENV 
response to IFN therapy in contrast to what occurs 
in HCV infection [14].
The response rate (62-83%) of treatment with 
INF of cases of CHC co-infected with TTV is the 
same whether RBV is added or not [15]. Moreo-
ver, the response of HCV to IFN/RBV therapy is not 
influenced by TTV concurrent infection [16].Addi-
tionally, the impact of SENV and TTV on the deve-
lopment of and progression of hepatic diseases is 
controversial [17]. 
We carried out this study to determine the preva-
lence of both SENV and TTV among HCV infected 
individuals in Egyptian patients and to detect their 
clinical significance.
Patients and methods
Study design
This cross sectional study was done in the Medical 
Microbiology and Immunology Department, Zaga-
zig, Faculty of Medicine and the University Hospi-
tals. The study protocol was reviewed and approved 
by the Institutional Review Board (IRB). A written 
informed consent was obtained from all patients. 
Patients and samples
Two hundred patients with chronic CHC infection 
(positive quantitative PCR for HCV for more than 
6 months) were enrolled in the study. They were 
HBs-Ag negative and had no history of other vi-
ral or autoimmune hepatitis. They were 92 males 
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and 108 females with ages ranging from (29-90) 
years, (M±SD: 55.2±14.5). For all patients, complete 
clinical assessmentand abdominal ultrasonography 
were done. 
Blood samples were collected and serum separa-
ted for liver function tests; aspartate aminotransfe-
rase (AST), alanine aminotransferase (ALT), albumin 
andbilirubin. All were measured by using (SAT 450 
turbidimetric assay, ELitech, USA). Quantitative PCR 
for HCV was done by Taq Man Assay Reagents, 
Applied Biosystems (Thermo Fisher Scientific, USA), 
using the 7500 fast Real Time PCR system with 
lower limit of detection 15 IU/ml (the procedure and 
primers used according to Abate et al. [18]). The 
remaining sera were stored at -80°C until used for 
SENV and TTV detection. 
Extraction of DNA from serum 
DNA was extracted from 200 μL serum using Ther-
mo Scientific, Gene JET Viral DNA and RNA Purifi-
cation kit (Thermo Fisher Scientific, USA) according 
to the manufacturer’s instructions.
Amplification and detection
SENV. The following components was added for 
each 20μL reaction: 10μL DreamTaq Green PCR 
Master Mix (2X), 20 pmol of each primer (Thermo 
Fisher Scientific, USA) (sense primer for SENV-D, 
“5´-GTAACTTTGCGGTCAACTGCC-3´”; sense pri-
mer for SENV-H, “5´-GGTGCCCCTWGTYAGTT-
GGCGGTT-3´” [W = A or T]; universal antisense 
primer,“5´-CCTCGGTTKSAAAKGTYTGATAGT-3´” 
[K = G or T, S = C or G, and Y= C or T]) [19] 
and 5 μL DNA template. They were amplified 
in a thermal cycler (Biometra, Germany) for 40 
cycles. Each cycle consisted of denaturation at 
95°C for 60 seconds, primer annealing at 55°C 
for 30 seconds, and extension at 72°C for 60 
seconds, with a final extension step at 72°C for 
10 minutes. 
TTV. A 20 µl PCR mixture containing 10 
μLDreamTaq Green PCR Master Mix (2X), 20 pmol 
of each primer(Thermo Fisher Scientific, USA) (Sen-
se primer; “5´-GCTACGTCACTAACCACGTG-3´”& 
antisense primer; “5´-CTBCGGTGTGTAAACT-
CACC-3´ [20] and 5 μL DNA template. It was ampli-
fied using a thermo-cycling program that consisted 
of an initial denaturation for 9 minutes at 95°C; 
and then 55 cycles of 20 seconds at 95°C, 20 se-
conds at 55°C, and 30 seconds at 72°C. Amplicons 
were also kept at 72°C for 5 minutes for further 
polymerization. 
Statistical data analysis
The statistical analysis was performed using IBM 
SPSS Statistics, version 24 (IBM; Armonk, New York, 
USA). Continuous data were expressed as means 
± standard deviation (SD) and compared using 
Student’s T test. Categorical variables were expres-
sed as percentage and compared using chi-square 
(χ2) test and Fisher’s exact probability test. A P value 
of ≤ 0.05 was considered significant
Results
Prevalence of SENV and TTV among 
chronic HCV patients
Out of 200 chronic HCV patients, 3 were positi-
ve for SENV-H demonstrated by the detection of 
a band of 230bp on gel electrophoresis. SENV-D 
was not detected in any case. Listed below are the 
clinical, physical, radiological and laboratory cha-
racteristics of the three cases from which SENV 
were identified.
Patient 1
A 60-year old male receiving furosemide, spirono-
lactone, and lactulose. He had moderate ascites. 
Ultrasonography showed cirrhotic liver. The body 
mass index was 27. Hemoglobin level was 11.5 g/
dL, platelet count was 65×103 U/L and total leu-
cocyte count was 2.4 ×103 U/L. The INR was 1.4. 
Liver function test results were: serum albumin 2.9 
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g/dL, total bilirubin 25.6 µmol/L, ALT 48U/L and 
AST 65 U/L, Alpha feto protein 20 ng/ml (ELISA 
kit; DiaMetra, Milano, Italy), antinuclear antibodies; 
negative (ANA ELISA kit, AESKULISA, Germany) and 
serum creatinine 0.9 µmol/L (SAT 450 turbidimetric 
assay, ELitech,USA). The patient was diagnosed to 
have ascites and was classified as Child Class B with 
Child Pugh Score 8 and MELD Score 12. He had 
no history of hemodialysis, positive history of blood 
transfusion (9 unit of blood), and positive history of 
previous surgery.
Virology testing revealed negative HBsAg and 
positive HCV G4a with a viral load of 5.3 log 10 
(copies/mL) TaqMan Real Time PCR with lower limit 
of detection 15 IU/ml.
Patient 2
A 72 year-old female receiving furosemide, spiro-
nolactone, lactulose, liver support, vitamine K and 
rantidine. She had mild ascites. Ultrasonography 
showed cirrhosis and focal mass. The body mass 
index was 18. Hemoglobin level was 10.5 g/dL, 
platelet count was 92×103 U/L and total leuco-
cyte count was 9×103 U/L. The INR was 1.7. Li-
ver function test results were: serum albumin 2.4 
g/dL, total bilirubin 29.07µmol/L, ALT 52U/L and 
AST 63U/L. Alpha feto protein 500 ng/ml (ELISA 
kit ;DiaMetra, Milano, Italy), antinuclear antibodies; 
negative (ANA ELISA kit, AESKULISA,Germany) 
and serum creatinine 0.9 µmol/L (by SAT 450 tur-
bidimetric assay, ELitech, USA). The patient was 
diagnosed to have hepatocellular carcinoma and 
was classified as Child Class B with Child Pugh 
Score 9 and MELD Score 14.
She had no history of hemodialysis or surgery and 
positive history of blood transfusion (6 units). Viro-
logic testing revealed negative HBsAg and positive 
HCV G4a with a viral load of 6.3 log10 (copies/mL) 
TaqMan Real Time PCR with lower limit of detection 
15 IU/ml.
Patient 3
A 53 year-old female receiving spironolactone, lac-
tulose, liver support, vitamin K, rantidine and cal-
cium supplement. Ultrasonography showed cirrho-
tic liver. The body mass index was 23. On exami-
nation she had hemoglobin level of 9 g/dL, platelet 
count of 110×103 U/L and total leucocyte count 
of 9×103 U/L. The INR was 1.2. Liver function test 
results were: serum albumin 3.3 g/dL, total biliru-
bin 22.2 µmol/l, ALT 47U/L and AST 54U/L. Alpha 
feto protein was 30ng /ml (ELISA kit;DiaMetra, Mi-
lano, Italy), antinuclear antibodies; negative(ANA 
ELISA kit, AESKULISA,Germany) and serum creati-
nine was 79.5 µmol/l (SAT 450 turbidimetric assay, 
ELitech,USA) The patient was diagnosed to have 
microcytic hypochromic anemia and was classified 
as Child Class B with Child Pugh Score 9 and MELD 
Score 14.
She had no history of hemodialysis or surgery, 
positive history of blood transfusion (4 units). Viro-
logic testing revealed negative HBsAg and positive 
HCV G4a with a viral load of 6.14 log 10 (copies/
mL) TaqMan Real Time PCR with lower limit of de-
tection 15 IU/ml.
Out of 200 chronic HCV patients, 21 (10.5%) 
were positive for TTV as demonstrated by visuali-
zation of a band of 199 bp on gel. A. Among the 
studied CHC patients; there were 92 male and 108 
female with mean age of 55.2. The level of HCV 
RNA log 10 by real time PCR ranged from (4.30-
7.59) copies/mL. On ultrasonographic examination; 
cirrhosis and focal mass were found in 27.5% of 
patients and cirrhosis only was detected in 53.5% 
of them. while 14% of patients had periportal fi-
brosis. Regarding laboratory investigations; total 
bilirubin, direct bilirubin, ALT and AST levels were 
elevated in 32%, 29.5%, 64% and 61% of patients 
respectively. Regarding risk factors; positive history 
of blood transfusion, positive history of previous 
surgery, positive history of Tattooing were reported 
in 61%, 74.5% and 27% of patients respectively, as 
shown in Table 1.
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Comparing laboratory and ultrasonography 
findings 
In 21 cases co-infected with (TTV&HCV) and 179 
cases (HCV positive& TTV negative), there were no 
statistically significance difference between both 
groups (P>.05), as shown in Table 2.
Comparing parental risk factors for TTV 
Between 21 cases co-infected with (TTV&HCV) and 
179 cases (HCV positive& TTV negative). The history 
of blood transfusion and history of surgery were sig-
nificantly higher in patients co-infected with (TTV& 
HCV) than the second group, as shown in Table 3.
Table 1.  Demography and characteristics of 200 in-
vestigated patients .
Characteristic
Patients 
no. %
Age (years)
mean±SD 55.2±14.5
Sex
Male 92 46
Female 108 54
HCV RNA, log10 (copies/mL)
median (range) 6.2 4.30-7.59
Cirrhosis 107 53.5
Cirrhosis and focal mass 55 27.5
Periportal fibrosis 28 14
Total bilirubin1 (mg/dL)
median (range) 0.70 0.4-3.5
Elevated 64 32
Direct bilirubin2 (mg/dL)
median (range) 0.2 0.1-1.6
Elevated 59 29.5
ALT3 (U/L)
median (range) 54 10-177
Elevated 128 64
AST4 (U/L)
median( range) 44 17-276
Elevated 122 61
Albumin5 (g/dL)
mean±SD 3.8±0.74
History of blood transfusion 122 61
History of previous surgery 149 74.5
Tattooing 54 27
HCV: hepatitis C virus, ALT: alanine aminotransferase, 
AST: aspartate-aminotransferase.
1: Normal level ¡(0-1mg/dl), 2: normal level (0-0.3 mg/dl), 
3: normal level (0-40U/L), 4: normal level (0-37U/L), 
5: normal level (3.5-5g/dL).
Table 2.  Biochemical and clinical characteristics of 
21 positive (TTV plus HCV) and 179 (only 
positive HCV) infected patients 
Characteristic
TTV positive TTV negative
P-valueHCV positive HCV positive
No. % No. %
Total bilirubin1
Elevated 6 28.6 58 32.4 0.81
Direct bilirubin2 
Elevated 6 28.6 53 29.6 >0.99
ALT3 
Elevated 13 61.9 115 64.3 0.81
AST4 
Elevated 10 47.6 112 62.6 0.24
Albumin (g/dL)
mean±SD 4±0.4 3.8±0.7 0.1
HCVRNA,log10 
(copies/mL)
6.14±0.3 6.08±0.6 .45
Cirrhosis 9 42.9 98 54,7
.081
cirrhosis
+focalmass 
5 23.8 50 27.9
Periportal 
fibrosis 
7 33.3 21 11.7
TTV: transfusion-transmitted virus, 
HCV: hepatitis C virus, ALT: alanine aminotransferase, 
AST: aspartate-aminotransferase. 
1: Normal level (0-1mg/dl), 2: normal level (0-0.3 mg/dl), 
3: normal level (0-40U/L), 4: normal level (0-37U/L).
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Table 3.  Comparison parental risk factors between 
21 positive patients (HCV + TTV) and those 
179 negative for co-infection with TTV. 
Characteristic
TTV positive TTV negative
P-valueHCV positive HCV positive
No. % No. %
History of blood 
transfusion 17 81
105 58.7 .048a
History of 
previous surgery 
20 95.2 129 72.1 .018a
Tattooing 3 14.3 5 28.5 .17
a: P<.05: statistically significance.
Discussion 
Further achievements have been made to bring 
HCV to the era of eradication. After the approval 
of DAAs in 2011, the therapeutic revolution against 
HCV involves pangenotypic HCV therapy which is 
a regimen combining two or three, 2nd generation 
DAAs. Duration of therapy is 8-16 weeks depen-
ding on the stage of fibrosis, genotype, baseline 
viral load, prior treatment history and pre-existing 
resistance-associated variants. Most of these combi-
nations have a high antiviral potency, fair tolerance 
and a reduced pill burden [21].
Contrary to studies carried out in Egypt or el-
sewhere, [11, 22-24] very low level of prevalence of 
SENV was identified in the current work. This can 
beattributed to technical or host factors. Technical 
factors include differences in the sensitivities of the 
assay systems [23], or primers used. In 2015, Abuo-
deh et al., concluded that the extensive variation in 
sequence of SENV made it difficult to select a primer 
set that can detect all virus genotypes [25]. Human 
factors are based on the possibility of the ubiqui-
tous distribution of SENV that could be affected by 
collaborations among behavioral, social, biological 
and climate factors [10]. Furthermore, the rate of 
clearance of SENV can contribute to variable rate of 
SENV among different populations. Umemura and 
colleagues in 2001, reported that about 77% of 
post transfusion infected patients have cleared the 
virus within 6 months after being infected and that 
13% appeared to have chronic SEN virus infection 
[26].
The three cases positive for SEN-V in the current 
work showed history of parenteral exposure through 
blood transfusion, tattoing and surgical procedures. 
These support the idea that SENV is transmitted via 
parental route.
The prevalence of TTV was 10.5% among CHC 
patients. Great variations in the prevalence of TTV 
have been reported in various studies. The prevalen-
ce of TTV infection in the current work falls within 
range reported before [27, 28]. However, it is lower 
than those identified in several other studies; 84.9% 
in Qatar, 90% in Pakistan and 47% in Taiwan [24-
25, 29] respectively. These variations can beattribu-
ted to differences in the quantity of viral DNA in 
the sera, different primers used, differences in the 
sensitivities of methods of detection, different study 
populations and different risk factors.
The prevalence of TTV was more in patients aged 
(50-70) years. This may be due to presence of large 
number of the patients in this study in this age 
group. 
The statistically- significant differences as regards 
history of blood transfusion and history of pre-
vious operations in patients positive for TTV versus 
TTV negative patients (p- value <.05) support the 
idea that TTV is transmitted parentally. This was 
in agreement with other studies [7, 10-11] which 
reported wide ranges of infection in intravenous 
drug users, hemophilic and thalassemic patients, 
patients on maintenance hemodialysis, HIV posi-
tive and patients with hepatic disease. The insig-
nificant difference regarding age, gender can be 
attributed to characters of the study population. 
On the other hand, the insignificant difference as 
regards tattooing is due to small number of cases 
practicing this procedure. 
This study found no statistically significant di-
fference between TTV positive and TTV negative 
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individuals regarding the level of AST, ALT, other 
laboratory and ultrasonography finding which agree 
with study of Bostan et al. [30], but contrary to 
other studies [8, 31]. Rocchi et al. [32] attributed 
the pathologic role of TTV to the capability of some 
isolates to activate production of pro-inflammatory 
cytokines, thus accelerate the severity of inflamma-
tory disorders.
Conclusion
The present study includes a small number of ca-
ses positive for SENV which does permit a definite 
conclusion. However, there was no significant co-
rrelation as regards the mean age or sex between 
TTV positive and TTV negative patients. TTV does 
not appear to have an impact on progression of 
hepatic diseases. The parenteral route seems to be 
critical in the transmission of TTV. 
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